Vaxxinity

Vaxxinity

Edit info

  • Founded: 2014
  • Location: Dallas, TX
  • Employee range: 50 - 200
  • Clinical stage: Clin3
  • Therapy area: COVID-19
  • Drug types: NEU, VAC, INF, CVV
  • Lead product: UB-612
  • Funding: $85M IPO Nov 2021


vaxxinity.com

linkedin.com

job board


Drug notes:

UB-311 Clin2 Alzheimer's; UB-312 Clin1 Parkinson's, DLB, MSA; UB-313 Clin1 migraine; VXX-401 Clin1 hypercholesterolemia; undisclosed RD/Clin0 Alzheimer's, undisclosed

About:

Vaxxinity is a pioneering biotechnology company dedicated to advancing vaccine development through innovative scientific approaches. Leveraging state-of-the-art molecular biology and immunology techniques, Vaxxinity focuses on designing next-generation vaccines that target chronic diseases, which are currently expensive treatments with less than 1% of the global population. Their scientific endeavors emphasize the use of novel antigen design, adjuvant technologies, and vaccine delivery systems to enhance efficacy, safety, and scalability. With a commitment to rigorous research and clinical validation, Vaxxinity aims to contribute significantly to public health by addressing current and emerging infectious and chronic threats with affordable treatments.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com